Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations

Clinical and Experimental Immunology

Volumn 178, Issue S1, 2014, Pages 151-152

  von Gunten, S ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; IMMUNOGLOBULIN; POLYSACCHARIDE; PROTEIN;

ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; DRUG INDICATION; GLYCOSYLATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN GLYCAN INTERACTION; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; METABOLISM; PASSIVE IMMUNIZATION; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; POLYSACCHARIDES; PROTEINS;

EID: 84921463091     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12550     Document Type: Article

References (10)

1. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367:2015-2025.
2. von Gunten S, Shoenfeld Y, Blank M etal. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat Rev Immunol 2014; 14:349.
3. von Gunten S, Simon HU. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 2010; 30 (Suppl. 1):S24-30.
4. von Gunten S, Vogel M, Schaub A etal. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007; 119:1005-1011.
5. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108:4255-4259.
6. Schaub A, von Gunten S, Vogel M etal. Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes. Allergy 2011; 66:1030-1037.
7. Jandus C, Boligan KF, Chijioke O etal. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 2014; 124:1810-1820.
8. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006; 1760:527-537.
9. Nizet V, Esko JD. Bacterial and viral infections. In: Varki A, Cummings RD, Esko JD etal. Essentials of glycobiology, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, The Consortium of Glycobiology Editors, La Jolla, CA, 2009:537-551.
10. von Gunten S, Smith DF, Cummings RD etal. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J Allergy Clin Immunol 2009; 123:1268-76.e15.